Form 4: Heron Therapeutics EVP, CFO Ira Duarte Reports Stock Transactions
SEC Form 4 Filing
Ira Duarte, EVP and CFO of Heron Therapeutics, reports the vesting of restricted stock units and subsequent acquisition of common stock on July 19, 2024.
Summary
- On July 19, 2024, Ira Duarte, the EVP and Chief Financial Officer of Heron Therapeutics, Inc., had 3,875 restricted stock units vest.
- These units converted into 3,875 shares of common stock.
- Following the transaction, Duarte directly owns 104,127 shares of common stock and 54,240 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions by a company executive, and doesn't inherently indicate positive or negative sentiment. It's a neutral event.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding the holdings and transactions of company insiders.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects a change in ownership by a company executive.
Key Dates
| Date | Description |
|---|---|
| 01/19/2024 | Date of grant for the restricted stock units, which vest in 16 equal quarterly installments beginning one quarter after this date. |
| 07/19/2024 | Date of transaction: vesting of restricted stock units and acquisition of common stock. |
| 07/22/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.